Showing results (231-240 of 636) with videos related to
Sort By:
Pageof 64
Nature Genetics|January 24, 2017
Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancerLuca Magnani, Gianmaria Frige, Raffaella Maria Gadaleta, et al.Nucleic Acids Research|September 20, 2013
Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cellsChun-Fui Lai, Koen D Flach, Xanthippi Alexi, et al.Nature Communications|November 28, 2015
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.Nature Communications|August 8, 2019
Author Correction: Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionVan T M Nguyen, Iros Barozzi, Monica Faronato, et al.Breast Cancer Research and Treatment|July 8, 2010
The liver receptor homolog-1 regulates estrogen receptor expression in breast cancer cellsPaul T R Thiruchelvam, Chun-Fui Lai, Hui Hua, et al.Cancer Research|July 30, 2009
The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activitySimak Ali, Dean A Heathcote, Sebastian H B Kroll, et al.Breast Cancer Research and Treatment|August 24, 2010
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growthRobert S Tolhurst, Ross S Thomas, Fiona J Kyle, et al.Breast Cancer Research and Treatment|August 22, 2014
Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancerBharath Rudraraju, Marjolein Droog, Tarek M A Abdel-Fatah, et al.Cell Reports|September 29, 2015
APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast CancerManikandan Periyasamy, Hetal Patel, Chun-Fui Lai, et al.Nature Communications|July 24, 2023
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclibR C Coombes, Sacha Howell, Simon R Lord, et al.Pageof 64